Glaukos Corp GKOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GKOS is a good fit for your portfolio.
News
-
Glaukos Announces the Release of its 2023 Sustainability Report
-
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
-
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
-
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
-
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
-
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
-
FDA Approves Glaukos' New Drug Application for iDose TR
Trading Information
- Previous Close Price
- $101.10
- Day Range
- $100.75–103.66
- 52-Week Range
- $45.38–103.66
- Bid/Ask
- $66.00 / $105.00
- Market Cap
- $5.07 Bil
- Volume/Avg
- 521,714 / 511,617
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.53
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 907
- Website
- https://www.glaukos.com
Comparables
Valuation
|
Metric
|
GKOS
|
SGHT
|
RXST
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 10.74 | 2.31 | 11.82 |
Price/Sales | 15.53 | 3.38 | 20.28 |
Price/Cash Flow | — | — | — |
Price/Earnings
GKOS
SGHT
RXST
Financial Strength
|
Metric
|
GKOS
|
SGHT
|
RXST
|
|---|---|---|---|
Quick Ratio | 4.53 | 12.44 | 7.05 |
Current Ratio | 5.34 | 13.29 | 8.06 |
Interest Coverage | −9.48 | −9.25 | −15.68 |
Quick Ratio
GKOS
SGHT
RXST
Profitability
|
Metric
|
GKOS
|
SGHT
|
RXST
|
|---|---|---|---|
Return on Assets (Normalized) | −11.38% | −23.43% | −17.04% |
Return on Equity (Normalized) | −22.25% | −31.87% | −21.78% |
Return on Invested Capital (Normalized) | −12.11% | −22.96% | −20.20% |
Return on Assets
GKOS
SGHT
RXST
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Zzqnlvq | Nlnprv | $185.5 Bil | |
SYK
| Stryker Corp | Fcvlsvdmgy | Pdlyp | $128.2 Bil | |
MDT
| Medtronic PLC | Yymrrwlls | Nkqqjlq | $106.7 Bil | |
BSX
| Boston Scientific Corp | Tssvbsxq | Tqrfbk | $99.0 Bil | |
DXCM
| DexCom Inc | Fymcmkhg | Gnxz | $53.1 Bil | |
EW
| Edwards Lifesciences Corp | Tcnbybzxr | Gtbjl | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Flfkjlrkq | Pgn | $24.9 Bil | |
ALGN
| Align Technology Inc | Tnqrlgtq | Fcfrn | $23.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Ndlddzlv | Rhymqs | $18.9 Bil | |
PODD
| Insulet Corp | Gklvgjjrj | Wbldj | $11.7 Bil |